0001410939-22-000048.txt : 20220406 0001410939-22-000048.hdr.sgml : 20220406 20220406181119 ACCESSION NUMBER: 0001410939-22-000048 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220404 FILED AS OF DATE: 20220406 DATE AS OF CHANGE: 20220406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SBLENDORIO GLENN CENTRAL INDEX KEY: 0001277478 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 22811647 MAIL ADDRESS: STREET 1: 3 TIMES SQAURE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: (609) 474-6755 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 wf-form4_164928306290708.xml FORM 4 X0306 4 2022-04-04 0 0001410939 IVERIC bio, Inc. ISEE 0001277478 SBLENDORIO GLENN C/O IVERIC BIO, INC. 8 SYLVAN WAY PARSIPPANY NJ 07054 1 1 0 0 CEO Common Stock 2022-04-04 4 S 0 50000 18.7561 D 229689 D The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. For a full discussion regarding the details of the Rule 10b5-1 trading plan adopted by the Reporting Person, refer to the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the the Securities and Exchange Commission on March 30, 2022. /s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio 2022-04-06